Welcome to our dedicated page for Disc Medicine SEC filings (Ticker: IRON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Disc Medicine filings document the regulatory and financial record of a clinical-stage biopharmaceutical company developing hematologic disease therapies. Its Form 8-K disclosures cover quarterly and annual financial results, corporate updates, clinical-program materials for bitopertin, DISC-0974 and DISC-3405, and FDA communications related to the bitopertin New Drug Application for erythropoietic protoporphyria.
The filing record also includes proxy materials covering board matters, executive compensation and shareholder voting items. Material-event reports describe Regulation FD presentations, operating runway disclosures, restructuring actions following regulatory developments, and risk-related statements around clinical trials, regulatory pathways, research spending and capital resources.
Disc Medicine, Inc. reported that board member Mona Ashiya, Ph.D., a Class I director, resigned from its Board of Directors effective October 3, 2025. She also stepped down from the Board’s Compensation Committee and Nominating and Corporate Governance Committee. The company stated that her resignation was not due to any disagreement with Disc Medicine regarding its operations, policies, or practices. Following her departure, the size of the Board was reduced from nine members to eight.
Georges Gemayel, a director of Disc Medicine, Inc. (ticker: IRON), was granted a stock option to purchase 1,000 shares of common stock on 09/16/2025 at an exercise price of $60.34 per share. The option is exercisable subject to vesting that occurs on the earlier of the company’s 2026 annual meeting or the one-year anniversary of the grant date, and it expires on 09/15/2035. The filing reports the option as a direct holding and shows 1,000 underlying shares following the transaction.
This Form 4 was submitted by an attorney-in-fact and signed on behalf of the reporting person on 09/18/2025. No other transactions or cash sales are disclosed in the filing.
Georges Gemayel, a director of Disc Medicine, Inc. (ticker: IRON), was granted a stock option to purchase 1,000 shares of common stock on 09/16/2025 at an exercise price of $60.34 per share. The option is exercisable subject to vesting that occurs on the earlier of the company’s 2026 annual meeting or the one-year anniversary of the grant date, and it expires on 09/15/2035. The filing reports the option as a direct holding and shows 1,000 underlying shares following the transaction.
This Form 4 was submitted by an attorney-in-fact and signed on behalf of the reporting person on 09/18/2025. No other transactions or cash sales are disclosed in the filing.
John D. Quisel, who serves as Chief Executive Officer and a director of Disc Medicine, Inc. (IRON), reported two related transactions dated 09/09/2025. He acquired 10,000 shares of common stock at $1.01 per share, bringing his total direct common stock holdings to 171,828 shares. On the same date he was granted or reported a stock option to buy 10,000 shares with an exercise price of $1.01, exercisable immediately and expiring 03/10/2030, increasing his total beneficial ownership including derivatives to 198,420 shares. The filing states the optioned shares are fully vested and exercisable as of the report date.
Kevin Bitterman, a director of Disc Medicine, Inc. (ticker: IRON), reported a sale of company stock under a pre-existing trading plan. On 08/22/2025 he sold 2,287 shares of common stock pursuant to a Rule 10b5-1 trading plan dated January 31, 2025, at a weighted average price of $61.03 per share (individual sale prices ranged from $60.95 to $61.05). The reporting person says he can provide a breakdown of shares sold at each price on request.
The report shows beneficial ownership held indirectly through Atlas-related investment vehicles: 590,621 shares in Atlas Venture Opportunity Fund I, LP; 420,549 shares in Atlas Venture Opportunity Fund II, LP; and 51,000 shares in Atlas Venture Fund XII, L.P. The filer disclaims beneficial ownership of those fund-held shares except to the extent of any pecuniary interest.
Form 144 filed for Disc Medicine, Inc. (IRON) reports a proposed sale of 2,287 shares of Common Stock through Merrill Lynch, with an aggregate market value of $136,648.25 and an approximate sale date of 08/22/2025 on Nasdaq. The shares were acquired in a private placement from the issuer on 05/01/2020 and paid in cash on that date. The filer reports no securities sold during the past three months for the account. The filing includes the standard representation that the seller is not aware of undisclosed material adverse information and references Rule 10b5-1 plan adoption language.
Disc Medicine, Inc. (IRON) filed a Form 144 reporting a proposed sale of 4,080 shares of common stock through Merrill Lynch, with an aggregate market value of $243,780.00. The filing shows the shares were acquired in a private placement from the issuer on 05/01/2020 and paid for in cash. The sale is scheduled to occur on or about 08/22/2025 and the shares are listed as traded on Nasdaq. The filer represents they are not aware of any undisclosed material adverse information about the issuer. No securities were reported sold by the filer in the past three months according to the form.
Disc Medicine director Kevin Bitterman reported sales of company common stock under a Rule 10b5-1 plan. The Form 4 shows sales on 08/13/2025 of 24,962 shares at a weighted-average price of $61.15 and on 08/14/2025 of 7,212 shares at a weighted-average price of $60.99, conducted pursuant to a 10b5-1 trading plan dated January 31, 2025. The filing lists substantial indirect holdings attributed to investment vehicles: 600,120 shares following the 08/13 sale and 592,908 shares following the 08/14 sale, plus additional holdings of 420,549 shares and 51,000 shares held by named funds. The report was signed by an attorney-in-fact on 08/15/2025.
Atlas Venture and affiliated funds reported holdings in Disc Medicine, Inc. This Amendment No. 4 to a prior Schedule 13D discloses that multiple Atlas Venture funds collectively beneficially own 2,148,984 shares of Disc Medicine common stock, representing an estimated 6.2% of outstanding shares based on 34,765,581 shares outstanding as of July 31, 2025. Individual fund holdings are reported as Atlas Venture Fund X: 1,084,527 shares (3.1%), Atlas Venture Fund XII: 51,000 shares (0.1%), Atlas Venture Opportunity Fund I: 592,908 shares (1.7%), and Atlas Venture Opportunity Fund II: 420,549 shares (1.2%). The filing states these reporting persons have shared voting and dispositive power over their respective shares and notes they "may be deemed" a group but explicitly disclaim group membership. The amendment references recent transactions in Exhibit 99.1 and updates prior Schedule 13D disclosures.
Disc Medicine, Inc. (IRON) submitted a Form 144 proposing the sale of 7,212 shares of Common Stock through Merrill Lynch, with an aggregate market value of $440,653.20. The filing lists 34,765,581 shares outstanding and an approximate sale date of 08/14/2025 on Nasdaq. The shares were originally acquired in a private placement on 05/01/2020 from the issuer and paid in cash. The filer reports no securities sold in the past three months and includes the standard representation about no undisclosed material information and compliance with Rule 10b5-1 if applicable.
Disc Medicine, Inc. (IRON) filed a Form 144 reporting a proposed sale of 12,862 shares of common stock through Merrill Lynch One Bryant Park (New York) with an aggregate market value of $785,868.20. The filing states the company has 34,765,581 shares outstanding and lists the approximate sale date as 08/14/2025 on the Nasdaq.
The securities were originally acquired on 05/01/2020 in a private placement from the issuer, paid in cash. The filer reports no securities sold in the past three months and includes the standard representation that the seller does not possess undisclosed material adverse information. The notice includes the usual signature and legal attestation language.